Morningstar

Roivant Sciences Ltd Ordinary Shares ROIV

Morningstar Rating

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire Sep 18, 2024 11:30am
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

GlobeNewswire Sep 10, 2024 10:30am
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

GlobeNewswire Sep 10, 2024 10:30am
Roivant Provides Update on Graves’ Disease Development Program

GlobeNewswire Sep 9, 2024 11:00am
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

GlobeNewswire Aug 8, 2024 11:00am
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

GlobeNewswire Jul 25, 2024 8:05pm
Pfizer shares downgraded as patent expirations loom

MarketWatch Jan 4, 2024 1:43pm
Roivant Sciences shares drop as lupus treatment misses trial goal

MarketWatch Nov 27, 2023 1:53pm
Trending: Roche to Buy Telavant From Roivant and Pfizer

Global News Select Oct 23, 2023 7:26pm
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

MarketWatch Oct 23, 2023 12:36pm
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion — Update

Global News Select Oct 23, 2023 8:01am
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal

Global News Select Oct 23, 2023 5:35am

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.